Selective CDK4/6 Inhibitors in Cancer: Moving Beyond Breast Cancer

In this downloadable slideset, Richard Finn, MD, Gary K. Schwartz, MD, and Geoffrey Shapiro, MD, PhD provide insight on the rationale for targeting cyclin dependent kinases 4 and 6 in cancer and highlight emerging clinical data with selective CDK4/6 inhibitors in multiple cancers.
Format: Microsoft PowerPoint (.ppt)
File Size: 598 KB
Released: April 14, 2017


Supported by an educational grant from
Pfizer, Inc.

Related Content

Downloadable slideset with highlights from key hematologic cancers as presented at EHA 2022 Congress, from Clinical Care Options (CCO)

Stéphane de Botton, MD Jesús F. San-Miguel, MD, PhD Alessandra Tedeschi, MD Released: June 30, 2022

Experts discuss important new data from ASCO 2022 that may impact treatment for chronic lymphocytic leukemia and mantle cell lymphoma, from Clinical Care Options (CCO)

Brad S. Kahl, MD Anthony Mato, MD, MSCE Released: June 30, 2022

Downloadable clinical resource with practical guidance on how to talk with your transgender patients about gender identity, including related terminology, from Clinical Care Options (CCO)

Nelson F. Sanchez, MD
Program Director
Released: June 30, 2022

From Clinical Care Options (CCO), download slides reviewing the integration of CAR T-cell therapy into community care

Jesús G. Berdeja, MD Caron A. Jacobson, MD Released: June 30, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings